View Older Stories View More Recent Stories
-
Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic MPM
-
BeyondSpring (BYSI) Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel
-
Merck (MRK) Reports Ten-Year Data for KEYTRUDA Demonstrated Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
-
Merck (MRK) Reports Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL 9
-
BMO Capital Reiterates Outperform Rating on Merck (MRK)
-
Merck (MRK) Falls 5% Following Data from Summit Therapeutics (SMMT)
-
Summit (SMMT): Ivonescimab Monotherapy Reduced Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC
-
Merck (MRK) and EyeBio Initiate Phase 2b/3 Trial for Restoret
-
TD Cowen Reiterates Buy Rating on Merck (MRK)
-
Merck (MRK) Announces EU Approval of KEYTRUDA Plus Padcev as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
-
Merck (MRK) Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
-
Merck (MRK) Announces Phase 3 Trial Initiation for Bomedemstat
-
Merck (MRK) Receives European Commission Approval for WINREVAIR (sotatercept)
-
3 ways to gain stock market exposure to the fertility theme
-
Merck (MRK) PT Lowered to $147 at Jefferies
-
Merck (MRK) to Acquire CN201 from Curon Biopharmaceutical
-
Merck (MRK) Provides Update on Phase 3 KeyVibe-008 Trial of an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab
-
Merck (MRK) tops earnings, revenue expectations but guidance mixed
-
Merck (MRK) Tops Q2 EPS by 12c, Beats on Revenue; Offers FY24 EPS Guidance
-
Merck (MRK) puts more active than calls with focus on with focus on August 120 puts into quarter results
-
Merck (MRK) August 2 weekly 125 straddle priced into quarter results
-
Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays
-
Merck (MRK) Declares $0.77 Quarterly Dividend; 2.5% Yield
-
Merck (MRK) Reports Topline Results from Phase 2b/3 Trial of Clesrovimab
-
10 policies if Trump wins and stock implications: Jefferies
-
Merck (MRK) Completes Acquisition of EyeBio
-
Morgan Stanley is out with its 'Top Stock Picks' list for Europe
-
Elanco Animal Health (ELAN) Completes Sale of Aqua Business to Merck (MRK)
-
Prelude Therapeutics Inc. (PRLD) Announces Clinical Collaboration with Mer zk to Evaluate PRT3789 plus KEYTRUDA
-
Merck (MRK) option IV flat into 2024 elections
-
Merck (MRK) and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat
-
Midday movers: Nvidia, Micron rise; Lennar, Tesla fall
-
Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
-
Wells Fargo Reiterates Equal Weight Rating on Merck (MRK)
-
Top pharma stocks to own in 2024 – Citi
-
Goldman Sachs just released the list of top stocks to own in February
